Overview of the 2007 food and drug administration circulatory system devices panel meeting on the endeavor zotarolimus-eluting coronary stent

Circulation

Volumn 117, Issue 12, 2008, Pages 1603-1608

  Pinto Slottow, Tina L ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Atherosclerosis; Drug eluting stents; Heart disease

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; ZOTAROLIMUS;

ANGIOCARDIOGRAPHY; ANTICOAGULATION; BARE METAL STENT; BLEEDING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY STENT; DRUG ELUTING STENT; FOOD AND DRUG ADMINISTRATION; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; NONHUMAN; PATIENT COMPLIANCE; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RESTENOSIS; REVIEW; ST SEGMENT; THROMBOSIS; TREATMENT DURATION;

CLINICAL TRIALS AS TOPIC; DRUG-ELUTING STENTS; HEART DISEASES; HUMANS; PLATELET AGGREGATION INHIBITORS; SIROLIMUS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 41149108455     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.752261     Document Type: Review

References (25)

1. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665-1671.
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S, for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496-501.
3. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M, for the Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
4. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30:1428-1436.
5. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, Morel MA, van Hout BA. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117-1124.
6. Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, Bakhai A, Cohen DJ, Kuntz RE, Ho KK. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004;110:1226-1230.
7. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
8. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004;292:2727-2734.
9. Hill RA, Dundar Y, Bakhai A, Dickson R, Walley T. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J. 2004;25:902-919.
10. The Cypher sirolimus-eluting coronary stent outperforms the Taxus stent in small coronary vessels according to new clinical data analysis published in the Journal of the American College of Cardiology. Available at: http://www.cordis.com/active/crdus/en_US/html/cordis/downloads/press/ 155_6027_1_SIRTAX_SmallVessels.pdf. Accessed October 11, 2007.
11. Boston Scientific Announces Implantation of Millionth TAXUS® Express2™ Coronary Stent System. Available at: http://bostonscientific. mediaroom.com/index.php?s=43&item=451. Accessed October 11, 2007.
12. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27:2784-2814.
13. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-1019.
14. Salmon S, LeNarz L, Leon MB, Mauri L, Kuntz RE. Endeavor zotarolimus-eluting coronary stent system: Medtronic vascular presentation. Presented at: FDA Circulatory System Devices Panel Meeting; October 10, 2007; Gaithersburg, Md. Available at: http://www.fda.gov/ohrms/dockets/ac/07/slides/ 2007-4322s1-02-final%20Sponsor%20Main%20Presentation_Medtronic.pdf. Accessed October 12, 2007.
15. Hillebrenner E, Farb A, Gao Y, Duggirala HJ. FDA Summary. Presented at: FDA Circulatory System Devices Panel Meeting; October 10, 2007; Gaithersburg, Md. Available at http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4322s1- 01_final%20-FDA%20Presentation.pdf. Accessed October 12, 2007.
16. Pocock SJ. Methodology of clinical research with drug-eluting stents. Presented at: European Society of Congress; September 2007; Vienna, Austria.
17. Serry R, Penny WF. Endothelial dysfunction after sirolimus-eluting stent placement. J Am Coll Cardiol. 2005;46:237-238.
18. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol. 2005;46:231-236.
19. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart JM, van Essen D, de Feyter PJ, Serruys PW. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006;27:166-170.
20. Togni M, Raber L, Cocchia R, Wenaweser P, Cook S, Windecker S, Meier B, Hess OM. Local vascular dysfunction after coronary paclitax-eleluting stent implantation. Int J Cardiol. 2007;120:212-220.
21. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289-2295.
22. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
23. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806.
24. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-1029.
25. Maisel WH. Drug eluting stents: post market surveillance. Presented at: FDA Circulatory System Devices Panel Meeting; October 10, 2007; Gaithersburg, Md. Available at: http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4322oph1- 01-Dr%20%20William%20Maisel's%20Presentation.pdf. Accessed October 12, 2007.